» Articles » PMID: 21223984

Microencapsulation of Inorganic Nanocrystals into PLGA Microsphere Vaccines Enables Their Intracellular Localization in Dendritic Cells by Electron and Fluorescence Microscopy

Overview
Specialty Pharmacology
Date 2011 Jan 13
PMID 21223984
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Biodegradable poly-(D,L-lactide-co-glycolide) microspheres (PLGA-MS) are approved as a drug delivery system in humans and represent a promising antigen delivery device for immunotherapy against cancer. Immune responses following PLGA-MS vaccination require cross-presentation of encapsulated antigen by professional antigen presenting cells (APCs). While the potential of PLGA-MS as vaccine formulations is well established, the intracellular pathway of cross-presentation following phagocytosis of PLGA-MS is still under debate. A part of the controversy stems from the difficulty in unambiguously identifying PLGA-MS within cells. Here we show a novel strategy for the efficient encapsulation of inorganic nanocrystals (NCs) into PLGA-MS as a tool to study their intracellular localization. We microencapsulated NCs as an electron dense marker to study the intracellular localization of PLGA-MS by transmission electron microscopy (TEM) and as fluorescent labels for confocal laser scanning microscopy. Using this method, we found PLGA-MS to be rapidly taken up by dendritic cells and macrophages. Co-localization with the lysosomal marker LAMP1 showed a lysosomal storage of PLGA-MS for over two days after uptake, long after the initiation of cross-presentation had occurred. Our data argue against an escape of PLGA-MS from the endosome as has previously been suggested as a mechanism to facilitate cross-presentation of PLGA-MS encapsulated antigen.

Citing Articles

Superparamagnetic Artificial Cells PLGA-FeO Micro/Nanocapsules for Cancer Targeted Delivery.

Wang T, Chang T Cancers (Basel). 2023; 15(24).

PMID: 38136352 PMC: 10741498. DOI: 10.3390/cancers15245807.


Sec22b and Stx4 Depletion Has No Major Effect on Cross-Presentation of PLGA Microsphere-Encapsulated Antigen and a Synthetic Long Peptide In Vitro.

Tondeur E, Voerman J, Geleijnse M, van Hofwegen L, van Krimpen A, Koerner J J Immunol. 2023; 211(8):1203-1215.

PMID: 37638825 PMC: 10592162. DOI: 10.4049/jimmunol.2200473.


PLGA Particles in Immunotherapy.

Horvath D, Basler M Pharmaceutics. 2023; 15(2).

PMID: 36839937 PMC: 9965784. DOI: 10.3390/pharmaceutics15020615.


Targeting of sialoadhesin-expressing macrophages through antibody-conjugated (polyethylene glycol) poly(lactic-co-glycolic acid) nanoparticles.

Van Hees S, Elbrink K, De Schryver M, Delputte P, Kiekens F J Nanopart Res. 2022; 24(3):65.

PMID: 35311024 PMC: 8919690. DOI: 10.1007/s11051-022-05451-1.


PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy.

Koerner J, Horvath D, Herrmann V, MacKerracher A, Gander B, Yagita H Nat Commun. 2021; 12(1):2935.

PMID: 34006895 PMC: 8131648. DOI: 10.1038/s41467-021-23244-3.